Search Result

Results for "

amyloid protein

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (145) 5-HT Receptor (4) Adenosine Deaminase (2) Adrenergic Receptor (3) Akt (1) Aldehyde Dehydrogenase (ALDH) (1) Amylin Receptor (2) Apoptosis (8) ATM/ATR (2) Autophagy (3) Bacterial (4) Beta-secretase (23) Calcium Channel (1) CaMK (2) Caspase (4) Cathepsin (1) CDK (2) Cholecystokinin Receptor (1) Cholinesterase (ChE) (7) Claudin (1) COX (1) Cyclophilin (1) DNA/RNA Synthesis (1) Dopamine Transporter (1) Drug Derivative (3) Drug Intermediate (1) Drug Isomer (1) Endogenous Metabolite (4) Ferroptosis (1) Fluorescent Dye (5) GABA Receptor (3) GCGR (1) GLUT (1) Glutathione Peroxidase (1) HDAC (3) Histamine Receptor (3) HyT (1) Interleukin Related (6) Isotope-Labeled Compounds (4) JNK (2) Keap1-Nrf2 (2) LDLR (1) Lipoxygenase (1) Microtubule/Tubulin (1) Mitochondrial Metabolism (3) MMP (1) Monoamine Oxidase (1) mRNA (1) mTOR (2) nAChR (2) Natriuretic Peptide Receptor (NPR) (1) NF-κB (7) NOD-like Receptor (NLR) (2) Phosphatase (3) Phosphodiesterase (PDE) (2) Phospholipase (1) PKC (2) Potassium Channel (1) Proteasome (1) Pyroptosis (1) Ras (1) Reactive Oxygen Species (ROS) (4) Reference Standards (9) Sigma Receptor (1) SOD (4) STAT (1) Tau Protein (9) TNF Receptor (1) Transmembrane Glycoprotein (1) Transthyretin (TTR) (3) Tyrosine Hydroxylase (1) α-synuclein (9) γ-secretase (10)
By Research Areas:	Cancer (15) Cardiovascular Disease (4) Endocrinology (4) Infection (4) Inflammation/Immunology (22) Metabolic Disease (8) Neurological Disease (181)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Transcription Factors (1) mRNA (1) siRNA drugs (2) Antisense Oligonucleotides (5) siRNAs (2)

209

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Targets Recommended: Amyloid-β

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P0265A

β-Amyloid (1-40) (human) TFA 5+ Cited Publications amyloid β-Peptide (1-40) (human) TFA; Aβ40 (human) TFA; Aβ(1-40) (human) TFA	Amyloid-β	Neurological Disease
β-Amyloid (1-40) TFA is a primary protein in plaques found in the brains of patients with Alzheimer's disease .

HY-16009

Buntanetap (+)-Phenserine; ANVS401	α-synuclein	Neurological Disease Inflammation/Immunology
Buntanetap ((+)-Phenserine) is a selective acetylcholinesterase inhibitor. Buntanetap is a multiple neurotoxic protein translation inhibitor with oral activity, including amyloid precursor protein (APP), α-synuclein (αSYN) and huntingtin protein (HTT). Buntanetap reduces the production of β-amyloid precursor protein by blocking its mRNA translation. Buntanetap has anti-inflammatory effects and can be used in the study of Alzheimer's disease and Parkinson's disease .

HY-13438

AZD3839 free base 2 Publications Verification	Beta-secretase	Neurological Disease
AZD3839 is an orally available, selective, reversible inhibitor of the β-site amyloid precursor protein cleaving enzyme BACE1 that can cross the blood-brain barrier. AZD3839 inhibits recombinant human BACE1 with a K_i=26.1 nM. AZD3839 inhibits A40 production in SH-SY5Y cells with an IC₅₀ of 4.8 nM. AZD3839 binds to BACE1 and reduces the Aβ amyloid produced by the cleavage of amyloid precursor protein (APP) by BACE1 and γ-secretase. AZD3839 can be used in the field of Alzheimer's disease research .

HY-148089

Eplontersen 1 Publications Verification	Transthyretin (TTR)	Neurological Disease
Eplontersen is a triantennary N-acetyl galactosamine (GalNAc₃-7a)-conjugated antisense oligonucleotide targeting transthyretin (TTR) mRNA to inhibit production of both variant and wild-type TTR protein. Misfolded TTR induces amyloid fibrils formation in the heart and peripheral nerves, leads to amyloid TTR (ATTR) amyloidosis diseases .

HY-P5096

*FITC-β-Ala-Amyloid* β-Protein (1-42)**	Amyloid-β	Neurological Disease
FITC-β-Ala-Amyloid β-Protein (1-42) is a FITC tagged Aβ1-42 peptide. Aβ1-42 plays a key role in the pathogenesis of Alzheimer’s disease .

HY-P0265C

β-Amyloid (1-40), HFIP-treated TFA 5+ Cited Publications	Amyloid-β	Neurological Disease
β-Amyloid (1-40), HFIP-treated is a β-Amyloid (1-40) (HY-P0265A) treated with HFIP. β-Amyloid (1-40) is a primary protein in plaques found in the brains of patients with Alzheimer's disease .

HY-P1466

β-Amyloid (1-16) amyloid β-protein (1-16)	Amyloid-β	Neurological Disease
β-Amyloid (1-16) is a β-Amyloid protein fragment involved in metal binding. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.

HY-P3908

*FITC-β-Ala-Amyloid* β-Protein (1-42) ammonium** 1 Publications Verification	Amyloid-β	Neurological Disease
FITC-β-Ala-Amyloid β-Protein (1-42) ammonium is a FITC tagged Aβ1-42 peptide. Aβ1-42 plays a key role in the pathogenesis of Alzheimer’s disease .

HY-50883

BMS 299897	γ-secretase	Neurological Disease
BMS 299897 is a sulfonamide γ-secretase inhibitor with an IC₅₀ of 7 nM for Aβ production inhibition in HEK293 cells stably overexpressing amyloid precursor protein (APP).

HY-P1903

β-Amyloid (35-42)	Amyloid-β	Neurological Disease
β-Amyloid (35-42) is a peptide consisting of amino acid of 35 to 42 of beta amyloid protein.

HY-124832

δ-Secretase inhibitor 11 1 Publications Verification	Caspase Amyloid-β	Neurological Disease
δ-Secretase inhibitor 11 (compound 11) is an orally active, potent, BBB-penetrated, non-toxic, selective and specific δ-secretase inhibitor, with an IC₅₀ of 0.7 μM. δ-Secretase inhibitor 11 interacts with both the active site and allosteric site of δ-secretase. δ-Secretase inhibitor 11 attenuates tau and APP (amyloid precursor protein) cleavage. δ-Secretase inhibitor 11 ameliorates synaptic dysfunction and cognitive impairments in tau P301S and 5XFAD transgenic mouse models. δ-Secretase inhibitor 11 can be used for Alzheimer's disease research .

HY-14537

Latrepirdine dihydrochloride Dimebolin dihydrochloride	Amyloid-β Histamine Receptor Adrenergic Receptor 5-HT Receptor Autophagy	Neurological Disease Endocrinology
Latrepirdine dihydrochloride is a neuroactive compound with antagonist activity at histaminergic, α-adrenergic, and serotonergic receptors. Latrepirdine stimulates amyloid precursor protein (APP) catabolism and *amyloid-β* (Aβ) secretion.

HY-P990301

Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2)	Amyloid-β	Neurological Disease
Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) is a mouse-derived IgG2b λ type antibody inhibitor, targeting to *Amyloid-beta. Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) recognizes unaggregated, oligomeric or fibrillar forms of Aβ42 and unaggregated Aβ40. Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) is selective for human Aβ42 over Aβ40, but not amyloid* precursor protein (APP). Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) can immunostain human or rat and mouse tissue. Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) can be used for detections of western blot, immunohistochemistry, immunofluorescence, immunoprecipitation and ELISA .

HY-103374

Phenserine (-)-Eseroline phenylcarbamate; (-)-Phenserine	Cholinesterase (ChE) Amyloid-β	Neurological Disease
Phenserine ((-)-Eseroline phenylcarbamate) is a derivative of Physostigmine (HY-N6608) and is a potent, noncompetitive, long-acting and selective AChE inhibitor. Phenserine reduces *β-amyloid* precursor protein (APP) and β-amyloid peptide (Aβ)** formation. Phenserine improves cognitive performance and attenuates the progression of Alzheimer's disease .

HY-P4882A

*(Pyr3)-Amyloid* β-Protein (3-42) TFA**	Amyloid-β	Neurological Disease
(Pyr3)-Amyloid β-Protein (3-42) TFA is the predominant amyloid β-peptide structure deposited in human brain of Alzheimer's disease and Down's syndrome patients. (Pyr3)-Amyloid β-Protein (3-42) TFA is suggested to accumulate in the brain and to trigger the formation of insoluble amyloid β-peptide deposits .

HY-P10040

(Gln22)β-Amyloid (1-40) human	Amyloid-β	Neurological Disease
(Gln22)β-Amyloid (1-40) human is an amyloid beta protein (Aβ)-containing peptide used in Alzheimer's disease research .

HY-14862

Latrepirdine Dimebolin; Dimebone	Amyloid-β Histamine Receptor Adrenergic Receptor 5-HT Receptor Autophagy	Endocrinology
Latrepirdine is a neuroactive compound with antagonist activity at histaminergic, α-adrenergic, and serotonergic receptors. Latrepirdine stimulates amyloid precursor protein (APP) catabolism and *amyloid-β* (Aβ) secretion.

HY-18292

ARN2966	Amyloid-β	Neurological Disease
ARN2966 is a potent, orally active and cross the blood-brain barrier amyloid precursor protein (APP) translation modulator.

HY-153430

Aβ/tau aggregation-IN-3	Amyloid-β	Neurological Disease
Aβ/tau aggregation-IN-3 is a potent amyloid protein aggregation inhibitor with an IC₅₀ of 0.85 μM by Aβ-Thioflavin T (Aβ-ThT) functional aggregation assay. Aβ/tau aggregation-IN-3 has anti-amyloid activity .

HY-128849

Eprodisate (70% in water)	Amyloid-β	Inflammation/Immunology
Eprodisate (70% in water) is an *amyloid* inhibitor that interferes with the interaction between amyloidogenic proteins and glycosaminoglycans, thereby inhibiting the aggregation of amyloid fibrils and the deposition of fibrils in tissues. Eprodisate (70% in water) slows the progression of renal disease associated with AA amyloidosis and may be useful for other types of amyloidosis .

HY-100936

Etazolate hydrochloride SQ 20009; EHT 0202 hydrochloride	Phosphodiesterase (PDE) GABA Receptor	Neurological Disease Inflammation/Immunology
Etazolate hydrochloride (SQ 20009) is an orally active, selective inhibitor of type 4 phosphodiesterase (PDE4) with an IC₅₀ of 2 μM. Etazolate hydrochloride is a γ-aminobutyric acid A (GABA_A) receptor regulator. Etazolate hydrochloride is an α-secretase activator and induced the production of soluble amyloid precursor protein (sAPPα). Etazolate hydrochloride, a pyrazolopyridine class derivative, increases cAMP levels. Etazolate hydrochloride has anxiolyticlike, antidepressant-like and anti-inflammatory effects .

HY-P1046

β-Amyloid (1-15) amyloid β-protein (1-15)	Amyloid-β	Neurological Disease
β-Amyloid (1-15) is a fragment of β-Amyloid peptide. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.

HY-P990011

Sabirnetug ACU-193	Amyloid-β	Neurological Disease
Sabirnetug is a humanized IgG2κ antibody targeting the Amyloid-β A4 precursor protein.

HY-P1468

β-Amyloid (1-28) amyloid β-protein (1-28)	Amyloid-β	Neurological Disease
β-Amyloid (1-28) is a β-Amyloid protein fragment involved in metal binding. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.

HY-P4885

Glp-amyloid-β (3-40) peptide (human) AβpE3-40	Amyloid-β	Neurological Disease
Glp-Amyloid-β (3-40) Peptide (human) (AβpE3-40) is a minor amounts of pyroglutamate-modified Aβ isolated from from 24-month-old Amyloid precursor protein (APP) transgenic Mice .

HY-50882

ELN318463	γ-secretase	Neurological Disease
ELN318463 is an amyloid precursor protein (APP) selective γ-secretase inhibitor. ELN318463 shows differential inhibition of presenilin (PS1)- and PS2-comprised γ-secretase with EC₅₀s of 12 nM and 656 nM for PS1 and PS2, respectively. ELN318463 is 51-fold more selective for PS1 .

HY-159083

DN5355	Amyloid-β	Neurological Disease
DN5355 is a small molecule compound that targets amyloid β protein (Aβ) and hyperphosphorylated tau protein. DN5355 can inhibit the aggregation of Aβ and tau protein and disaggregate the formed Aβ and tau protein fibers. DN5355 can be used in the study of Alzheimer's disease .

HY-P4882

*(Pyr3)-Amyloid* β-Protein (3-42)**	Amyloid-β	Neurological Disease
(Pyr3)-Amyloid β-Protein (3-42) is the predominant amyloid β-peptide structure deposited in human brain of Alzheimer's disease and Down's syndrome patients. (Pyr3)-Amyloid β-Protein (3-42) is suggested to accumulate in the brain and to trigger the formation of insoluble amyloid β-peptide deposits .

HY-P4788

*Acetyl-Amyloid* β-Protein (1-6) amide**	Amyloid-β	Neurological Disease
Acetyl-Amyloid β-Protein (1-6) amide is a hexapeptide that contains a potential copper(II) binding site. Acetyl-Amyloid β-Protein (1-6) amide can be used for research of Alzheimer's disease and related disorders .

HY-P1894

*β-Amyloid* Protein Precursor 770 (135-155)**	Amyloid-β	Neurological Disease
β-Amyloid Protein Precursor 770 (135-155) is a peptide of amyloid precursor protein isoform (APP 770). APP 770 produces Aβ40/42 .

HY-P3780

*Cys-Gly-Lys-Lys-Gly-Amyloid* β-Protein (36-42)**	Amyloid-β	Neurological Disease
Cys-Gly-Lys-Lys-Gly-Amyloid β-Protein (36-42) is the 36-42 fragment of Amyloid β-Protein. β-amyloid, a polypeptide made up of 36-43 amino acids, is the main component of amyloid plaques found in the brains of people with Alzheimer's disease. β-amyloid oligomers (Aβos) plays A key role in the progression of Alzheimer's disease (AD) by inducing neuronal damage and cognitive impairment .

HY-P4886A

Amyloid β-Protein (3-42) TFA	Amyloid-β	Neurological Disease
Amyloid β-Protein (3-42) TFA is a precursor of Pyr peptide. Pyroglutamic acid-modified Aβ (pEAβ) (3-42) is the core of the amyloid plaque in Alzheimer's disease. pEAβ (3-42) accelerates the aggregation of Aβ(1-42), while Aβ(1-42) significantly slows down the primary and secondary nucleation of pEAβ(3-42).

HY-P3779

Amyloid 17-42 Aβ(17-42)	Apoptosis	Neurological Disease
Amyloid 17-42 (Aβ(17-42)) is a major constituent of diffuse plaques in Alzheimer's disease and cerebellar pre-amyloid in Down's syndrome, derived by alpha- and gamma-secretase cleavage of *the amyloid* precursor protein (APP)*. Amyloid* 17-42 can induce neuronal apoptosis via a Fas-like/caspase-8 activation pathway .

HY-126047

(S)-(-)-Anatabine	NF-κB Beta-secretase	Neurological Disease
(S)-(-)-Anatabine is an NFκB/BACE-1 inhibitor with blood-brain barrier penetration. (S)-(-)-Anatabine inhibits NFκB activation via phosphorylation of its p65 subunit. (S)-(-)-Anatabine inhibits BACE-1 transcription and reduces BACE-1 protein levels. (S)-(-)-Anatabine lowers production of Aβ_1-40 and Aβ_1-42 by reducing β-cleavage of amyloid precursor protein without affecting α-cleavage. (S)-(-)-Anatabine can be used for the research of Alzheimer's disease .

HY-121817

Sulfiram	Aldehyde Dehydrogenase (ALDH) Drug Intermediate Amyloid-β	Infection Neurological Disease
Sulfiram is a very weak aldehyde dehydrogenase (ALDH) inhibitor, with an IC₅₀ value of 413 μM against Saccharomyces cerevisiae ALDH. As a photochemical precursor, Sulfiram undergoes photoconversion to form Disulfiram (HY-B0240), a potent ALDH inhibitor. Sulfiram inhibits the dimerization of the extracellular domain fragment (amino acid residues 230-624) of amyloid precursor protein (APP), alters the monomer-dimer equilibrium, induces conformational changes in the fragment, and enhances the production of sAPPα via α-cleavage of APP. Sulfiram can be used in research related to scabies and Alzheimer's disease .

HY-P991130

Dalidnetug	Amyloid-β	Neurological Disease
Dalidnetug is a humanized monoclonal antibody targeting human amyloid-beta precursor protein (APP). Dalidnetug specifically binds to APP to reduce the production of amyloid-beta (Aβ), thus exerting the activity of clearing amyloid-beta. Dalidnetug is promising for research of Alzheimer's disease .

HY-177646

Mivelsiran ALN-APP	Amyloid-β	Neurological Disease
Mivelsiran is a siRNA targeted to amyloid-beta precursor protein (APP). It is used for the study of Alzheimer's disease.

HY-16009B

Buntanetap L-Tartrate (+)-Phenserine L-Tartrate; ANVS401 L-Tartrate	Amyloid-β	Neurological Disease
Buntanetap L-Tartrate (Phenserine L-Tartrate) is a selective AChE inhibitor (IC₅₀ = 22.2 nM). Buntanetap is a multiple neurotoxic protein translation inhibitor with oral activity, including amyloid precursor protein (APP), α-synuclein (αSYN) and huntingtin protein (HTT). Buntanetap reduces the production of β-amyloid precursor protein by blocking its mRNA translation. Buntanetap has anti-inflammatory effects and can be used in the study of Alzheimer's disease and Parkinson's disease .

HY-P1051

β-Amyloid (12-28) amyloid β-protein (12-28)	Amyloid-β	Neurological Disease
β-Amyloid (12-28) (Amyloid β-Protein (12-28)) is a peptide fragment of β-amyloid protein (β1-42). β1-42, a 42 amino acid protein , is the major component of senile plaque cores. β-Amyloid (12-28) shows aggregation properties. β-Amyloid (12-28) has the potential for Alzheimer’s disease research .

HY-P3846

*(Glu20)-Amyloid* β-Protein (1-42)**	Amyloid-β	Neurological Disease
(Glu20)-Amyloid β-Protein (1-42) is a slower fibrillizing variant of amyloid β-protein (Aβ). The Glu20 mutation reduces the aggregation propensity of Aβ42 and prevents accumulation of the slowly fibrillizing peptide. Amyloid β-protein is the primary component of both vascular and parenchymal amyloid deposits in Alzheimer's disease .

HY-P4391

*(Asp37)-Amyloid* β-Protein (1-42)**	Amyloid-β	Neurological Disease
(Asp37)-Amyloid β-Protein (1-42) is the G37D mutant of wild-type Amyloid-beta (1-42) peptide .

HY-P4892

Amyloid β-Protein (4-42)	Amyloid-β	Others
Amyloid β-Protein (4-42) is aAβ Fragment.

HY-P4884

Amyloid β-Protein (1-46)	Amyloid-β	Others
Amyloid β-Protein (1-46) is aAβ Fragment.

HY-P3859

*Cys-Gly-Lys-Arg-Amyloid* β-Protein (1-42)**	Amyloid-β	Neurological Disease
Cys-Gly-Lys-Arg-Amyloid β-Protein (1-42) is a peptide fragment of amyloid β-protein (Aβ). Cys-Gly-Lys-Arg-Amyloid β-Protein (1-42) can be used in research of Alzheimer's disease .

HY-P1894A

*β-Amyloid* Protein Precursor 770 (135-155) TFA**	Amyloid-β	Neurological Disease
β-Amyloid Protein Precursor 770 (135-155) TFA is a peptide of amyloid precursor protein isoform (APP 770). APP 770 produces Aβ40/42 .

HY-P4886

Amyloid β-Protein (3-42)	Amyloid-β	Neurological Disease
Amyloid β-Protein (3-42) is the precursor of Pyr peptide. Pyroglutamate-modified Aβ (pEAβ) (3-42) is the core of the amyloid template block in Alzheimer's disease. pEAβ(3-42) accelerated the aggregation of Aβ(1-42), while Aβ(1-42) significantly slowed the primary and secondary nucleation of pEAβ(3-42) .

HY-P10494

FEFEFKFK	Amyloid-β	Neurological Disease
FEFEFKFK is an octapeptide that self-assembles into fibrillar structures. FEFEFKFK is able to form gels at concentrations greater than about 7 mg/mL. The self-assembly and gelation properties of FEFEFKFK help to understand the mechanism of amyloid fibril formation in protein misfolding diseases such as Alzheimer's disease and Parkinson's disease .

HY-50882A

ELN318463 racemate	γ-secretase	Neurological Disease
ELN318463 racemate is the racemate of ELN318463. ELN318463 is an amyloid precursor protein (APP) selective γ-secretase inhibitor. ELN318463 shows differential inhibition of presenilin (PS1)- and PS2-comprised γ-secretase with EC₅₀s of 12nM and 656 nM for PS1and PS2, respectively. ELN318463 is 51-fold more selective for PS1 .

HY-P3782

*(Met(O2)35)-Amyloid* β-Protein (1-42)**	Amyloid-β	Others
(Met(O2)35)-Amyloid β-Protein (1-42) is a peptide .

HY-P0265AS

β-Amyloid-15N (1-40) TFA amyloid Beta-Peptide-15N (1-40) (human) TFA; amyloid β-Peptide-15N (1-40) (human) TFA	Amyloid-β	Neurological Disease
β-Amyloid- ¹⁵N (1-40) (TFA) is the ¹⁵N-labledβ-Amyloid (1-40) (TFA). β-Amyloid (1-40) is a primary protein in plaques found in the brains of patients with Alzheimer's disease .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0044

Ginsenoside Re 4 Publications Verification Ginsenoside B2; Panaxoside Re; Sanchinoside Re	Panax ginseng C. A. Meyer Triterpenes Neurological Disease Classification of Application Fields Terpenoids Plants Endogenous metabolite Disease Research Fields Araliaceae Source Classification Cancer	Amyloid-β NF-κB JNK Endogenous Metabolite
Ginsenoside Re (Ginsenoside B2) is an extract from Panax notoginseng. Ginsenoside Re decreases the *β-amyloid* protein (Aβ). Ginsenoside Re plays a role in antiinflammation through inhibition of JNK and NF-κB.

HY-N0931

Santacruzamate A Maximum Cited Publications 19 Publications Verification CAY-10683	Alkaloids Microorganisms other families Classification of Application Fields Other Alkaloids Plants Disease Research Fields Source Classification Cancer	HDAC Amyloid-β
Santacruzamate A (CAY-10683, STA) is a potent and selective HDAC2 inhibitor with an IC₅₀ of 119 pM. STA also exerts neuroprotective property against amyloid-β protein fragment 25–35. STA can be used for cancer and neurological disease research .

HY-12688A

Succinyl phosphonate trisodium salt 10+ Cited Publications	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification Cancer	Mitochondrial Metabolism Reactive Oxygen Species (ROS) Amyloid-β
Succinyl phosphonate trisodium salt is a α-Ketoglutarate Dehydrogenase Complex (KGDHC) modulator with neuroprotective activity. Succinyl phosphonate trisodium salt protects this complex, reduces cellular succinyl-CoA concentration, downregulates protein succinylation levels, and inhibits the activity of the α-ketoglutarate dehydrogenase complex. Succinyl phosphonate trisodium salt corrects hypoxic or ethanol-induced behavioral impairments, modulates exploratory behavior and emotional stress responses, and improves hypoxia tolerance. Succinyl phosphonate trisodium salt reduces glutamate excitotoxicity, restores the activity of the α-ketoglutarate dehydrogenase complex, reverses the changes in glutamate dehydrogenase and glutamine synthetase activities induced by β-amyloid (Amyloid-β), modulates cognitive function, and prevents β-amyloid-induced neuronal damage. Succinyl phosphonate trisodium salt improves microglial senescence, alleviates neuroinflammation, reactive oxygen species (ROS) production, lipid peroxidation, and the expression of proinflammatory cytokines. Succinyl phosphonate trisodium salt can be used in the research of Alzheimer's disease, aging-related neuroinflammation, and Parkinson's disease .

HY-113283

Homogentisic acid	Structural Classification Other disease Classification of Application Fields Ketones, Aldehydes, Acids Disease markers Phenols Polyphenols Metabolic Disease Endogenous metabolite Disease Research Fields	Amyloid-β Natriuretic Peptide Receptor (NPR) α-synuclein Transthyretin (TTR) Claudin
Homogentisic acid is an orally active, blood-brain barrier-permeable amyloidogenic compound that functions as both an amyloid component and a pigment precursor. Accumulation of homogentisic acid downregulates tight junction proteins (such as claudin-5, occludin, ZO-1) and impairs blood-brain barrier integrity. Homogentisic acid and its oxidation product benzoquinone acetic acid not only induce the aggregation and fibrosis of multiple proteins (such as Aβ_1-42, α-synuclein, SAA, Transthyretin (TTR), atrial natriuretic peptide), but also trigger oxidative stress, damage to the Wnt/β-catenin pathway, and neurotoxicity, leading to ochronosis pigment deposition and synaptic dysfunction. At specific concentrations, homogentisic acid exerts no cytotoxicity or genotoxicity on human peripheral blood lymphocytes, and even counteracts the genotoxicity induced by Irinotecan (HY-16562). Homogentisic acid serves as an important tool molecule for investigating the mechanisms of diseases including ochronosis, secondary amyloidosis, Alzheimer's disease, and colorectal cancer .

HY-N7368

Hibifolin	Flavonols Flavonoids other families Neurological Disease Classification of Application Fields Phenols Polyphenols Plants Inflammation/Immunology Disease Research Fields Source Classification	Adenosine Deaminase Bacterial Caspase
Hibifolin is a flavonol glycoside that can be isolated from Helicteres isora. Hibifolin is an inhibitor of adenosine deaminase (ADA) (K_i = 49.92 μM). Hibifolin protects neurons against β-amyloid-induced neurotoxicity. Hibifolin possesses a potent protective activity against cell death induced by aggregated Aβ. Hibifolin can abolish Aβ-induced caspase-3 and caspase-7 activation. Hibifolin induces Akt phosphorylation in cortical neurons. Hibifolin is also a natural sortase A (SrtA) inhibitor (IC₅₀ = 31.2 μM) through direct binding to SrtA protein. Hibifolin attenuates the pathogenic behavior of Staphylococcus aureus including adhesion, invasion, and biofilm formation. Hibifolin improves the survival of pneumonia induced by Staphylococcus aureus in mouse model and alleviates pathological damage. Hibifolin shows a synergistic antibacterial effect with Cefotaxime (HY-A0088A) .

HY-W010041

Scyllo-Inositol	Natural Products Endogenous metabolite Source Classification	α-synuclein Amyloid-β
Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and *Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein* homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease .

HY-139066

Punicic acid 1 Publications Verification Trichosanic acid	Structural Classification Punica granatum L. Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Punicaceae Plants Disease Research Fields Source Classification	TNF Receptor GLUT Proteasome Tau Protein PKC
Punicic acid is a bioactive compound of pomegranate seed oil. Punicic acid is an isomer of conjugated α-linolenic acid and ω-5 polyunsaturated fatty acids. Punicic acid has anti-inflammatory and antioxidant activities and can inhibit the expression of inflammatory mediators such as tumor necrosis factor α (TNF-α). Punicic acid can also reduce the formation of β-amyloid deposits and hyperphosphorylation of tau by increasing the expression of GLUT4 protein and inhibiting the overactivation of calpain, and is used to prevent and treat neurodegenerative diseases. In addition, punicic acid also has breast cancer inhibitor properties that depend on lipid peroxidation and PKC pathways .

HY-116753

(-)Clausenamide	Clausena lansium (Lour.) Skeels Rutaceae Plants Source Classification	Amyloid-β Tau Protein
(-)Clausenamide is an active alkaloid isolated from the leaves of Clausena lansium (Lour.) Skeels, and improves cognitive function in both normal physiological and pathological conditions. (-)Clausenamide inhibits *β-amyloid* (Aβ) toxicity, blocking neurofibrillary tangle formation by inhibiting the phosphorylation of tau protein. (-)Clausenamide exerts a significant neuroprotective activity against Aβ_25-35. (-)Clausenamide can be used for researching Alzheimer's disease (AD) .

HY-N12540

Monogalactosyldiacylglycerol MGDG	Structural Classification other families Oplismenus burmannii Plants Lipid Source Classification	DNA/RNA Synthesis Apoptosis
Monogalactosyldiacylglycerol (MGDG) is a galactolipid with anti-inflammatory and anticancer activities, which is found in photosynthetic organisms. Monogalactosyldiacylglycerol is a potent DNA polymerase inhibitor with pro-apoptotic activity. Monogalactosyldiacylglycerol inhibits the synthesis of LPS (HY-D1056)-induced inflammation-related proteins (Ex-FABP, Avidin, *Serum Amyloid* A**). Monogalactosyldiacylglycerol exerts an anti-proliferative effect on chicken articular chondrocytes . Monogalactosyldiacylglycerol can be used in research related to osteoarthritis, cancer and inflammatory diseases .

HY-N13742

Dihydrohonokiol B Dihydrohonokiol	Philadelphus coronarius L. Magnoliaceae Phenols Polyphenols Plants Source Classification	GABA Receptor
Dihydrohonokiol B (Dihydrohonokiol) is an anxiolytic agent. Dihydrohonokiol B can reduce the neurotoxicity induced by amyloid β protein by stimulating the GABA_C receptor. Dihydrohonokiol B can be used in the research of neurodegenerative diseases such as Alzheimer's disease .

HY-12688

Succinyl phosphonate	Structural Classification Neurological Disease Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Source Classification	Mitochondrial Metabolism Reactive Oxygen Species (ROS) Amyloid-β
Succinyl phosphonate is a α-Ketoglutarate Dehydrogenase Complex (KGDHC) modulator with neuroprotective activity. Succinyl phosphonate protects this complex, reduces cellular succinyl-CoA concentration, downregulates protein succinylation levels, and inhibits the activity of the α-ketoglutarate dehydrogenase complex. Succinyl phosphonate corrects hypoxic or ethanol-induced behavioral impairments, modulates exploratory behavior and emotional stress responses, and improves hypoxia tolerance. Succinyl phosphonate reduces glutamate excitotoxicity, restores the activity of the α-ketoglutarate dehydrogenase complex, reverses the changes in glutamate dehydrogenase and glutamine synthetase activities induced by β-amyloid (Amyloid-β), modulates cognitive function, and prevents β-amyloid-induced neuronal damage. Succinyl phosphonate improves microglial senescence, alleviates neuroinflammation, reactive oxygen species (ROS) production, lipid peroxidation, and the expression of proinflammatory cytokines. Succinyl phosphonate can be used in the research of Alzheimer's disease, aging-related neuroinflammation, and Parkinson's disease .

HY-N14323

Madindoline A	Structural Classification Natural Products Microorganisms Source Classification	Interleukin Related STAT
Madindoline A is an orally active gp130 antagonist with a K_D of 288 μM. Madindoline A inhibits IL-6- and IL-11-induced osteoclastogenesis, suppresses IL-6-stimulated serum amyloid A protein production, inhibits bone resorption and bone loss, and also inhibits IL-6- and IL-11-dependent cell line growth, as well as IL-6-dependent Stat3 tyrosine phosphorylation. Madindoline A is applicable for the research of hormone-dependent postmenopausal osteoporosis .

HY-129133

cis-Miyabenol C	Vitis vinifera cv. Zalema Phenols Plants Vitaceae Source Classification	Drug Isomer
cis-Miyabenol C is an isomer of the resveratrol trimer Miyabenol C, which can be isolated from grape herbs. Miyabenol C is an inhibitor of *β-amyloid* (Aβ) and amyloid β precursor protein (APP) in Alzheimer's disease model mice, and inhibit β-secretase activity without changing the protein level of β-secretase BACE1 .

HY-N12321

2',3'-Dihydroxy-4',6'-dimethoxychalcone	Monophenols Labiatae Ulex europaeus L. Phenols Plants Source Classification	Others
2',3'-Dihydroxy-4',6'-dimethoxychalcone (compound 1) can inhibit Amyloid β-protein (Aβ42) fibrillization and aggregation. 2',3'-Dihydroxy-4',6'-dimethoxychalcone has oral activity and can be detected in the brain .

HY-N0044R

Ginsenoside Re (Standard) Ginsenoside B2(Standard); Panaxoside Re(Standard); Sanchinoside Re (Standard)	Panax ginseng C. A. Meyer Neurological Disease Classification of Application Fields Terpenoids Plants Endogenous metabolite Disease Research Fields Araliaceae Source Classification Cancer	Reference Standards Amyloid-β NF-κB JNK Endogenous Metabolite
Ginsenoside Re (Standard) is the analytical standard of Ginsenoside Re. This product is intended for research and analytical applications. Ginsenoside Re (Ginsenoside B2) is an extract from Panax notoginseng. Ginsenoside Re decreases the *β-amyloid* protein (Aβ). Ginsenoside Re plays a role in antiinflammation through inhibition of JNK and NF-κB.

HY-W010041R

Scyllo-Inositol (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards α-synuclein Amyloid-β
Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease .

HY-N0931R

Santacruzamate A (Standard) CAY-10683 (Standard)	Alkaloids Microorganisms other families Other Alkaloids Plants Source Classification	Reference Standards HDAC Amyloid-β
Santacruzamate A (Standard) is the analytical standard of Santacruzamate A. This product is intended for research and analytical applications. Santacruzamate A (CAY-10683, STA) is a potent and selective HDAC2 inhibitor with an IC50 of 119 pM. STA also exerts neuroprotective property against amyloid-β protein fragment 25–35. STA can be used for cancer and neurological disease research[1][2].

HY-N7368R

Hibifolin (Standard)	Flavonols Structural Classification Flavonoids other families Phenols Polyphenols Plants Source Classification	Reference Standards Adenosine Deaminase Bacterial Caspase
Hibifolin (Standard) is the analytical standard of Hibifolin. This product is intended for research and analytical applications. Hibifolin is a flavonol glycoside that can be isolated from Helicteres isora. Hibifolin is an inhibitor of adenosine deaminase (ADA) (K_i = 49.92 μM). Hibifolin protects neurons against β-amyloid-induced neurotoxicity. Hibifolin possesses a potent protective activity against cell death induced by aggregated Aβ. Hibifolin can abolish Aβ-induced caspase-3 and caspase-7 activation. Hibifolin induces Akt phosphorylation in cortical neurons. Hibifolin is also a natural sortase A (SrtA) inhibitor (IC₅₀ = 31.2 μM) through direct binding to SrtA protein. Hibifolin attenuates the pathogenic behavior of Staphylococcus aureus including adhesion, invasion, and biofilm formation. Hibifolin improves the survival of pneumonia induced by Staphylococcus aureus in mouse model and alleviates pathological damage. Hibifolin shows a synergistic antibacterial effect with Cefotaxime (HY-A0088A) .

HY-N13064

2,2′,4,4′-Tetrahydroxychalcone	Structural Classification Phenols Polyphenols Morus alba L. Plants Moraceae Source Classification	Drug Derivative Beta-secretase Amyloid-β
2,2′,4,4′-Tetrahydroxychalcone (Compound 18) is a selective and potent BACE1 inhibitor with an IC₅₀ of 0.62 μM. 2,2′,4,4′-Tetrahydroxychalcone is a derivative of Isoliquiritigenin (HY-N0102) found in Glycyrrhiza uralensis. 2,2′,4,4′-Tetrahydroxychalcone can block the β-cutting step of amyloid precursor protein (APP), thereby reducing the production of *β-amyloid* (Aβ) peptide. 2,2′,4,4′-Tetrahydroxychalcone can be used for research of Alzheimer’s disease .

HY-W720917

Junicedric acid	Structural Classification Pinaceae Terpenoids Diterpenoids Plants Pinus merkusii Jungh. & de Vriese Source Classification	CaMK PKC Amyloid-β Apoptosis
Junicedric acid is a diterpenoid compound that can be isolated from the resin of the Araucaria araucana tree. Junicedric acid exerts neuroprotective activity by increasing intracellular calcium levels in hippocampal neurons, activating PKC and *calcium/calmodulin-dependent protein* kinase (CaMKII), and preventing Amyloid-β** oligomer-induced synaptic protein loss, apoptosis, and long-term potentiation (LTP) inhibition. Junicedric acid can be used in the study of the pathological mechanisms of neurodegenerative diseases such as Alzheimer's disease .

Cat. No.	Product Name	Chemical Structure

HY-137315S

TML-6-d3
TML-6-d₃ is the deuterium labeled TML-6. TML-6, an orally active curcumin derivative, inhibits the synthesis of the β-amyloid precursor protein and β-amyloid (Aβ). TML-6 can upregulate Apo E, suppress NF-κB and mTOR, and increase the activity of the anti-

HY-P0265AS

β-Amyloid-15N (1-40) TFA
β-Amyloid- ¹⁵N (1-40) (TFA) is the ¹⁵N-labledβ-Amyloid (1-40) (TFA). β-Amyloid (1-40) is a primary protein in plaques found in the brains of patients with Alzheimer's disease .

HY-P1363S1

β-Amyloid (1-42), human, Ala(13C3,15N) TFA

β-Amyloid (1-42), human, Ala( ¹³C₃, ¹⁵N) TFA is the ¹³C and ¹⁵N-labeled β-Amyloid (1-42), human (HY-P1363A). β-Amyloid (1-42) (Amyloid β-peptide (1-42)), human, a 42-amino acid peptide that has not been treated with HFIP, is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human, after being monomericized by HFIP and dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4 °C, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37 °C to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death .

HY-132580S

Tofersen-d27

Tofersen-d₂₇ (BIIB067-d₂₇) is the deuterium labeled Tofersen (HY-132580). Tofersen (BIIB067) is an antisense oligonucleotide and SOD1 mRNA inhibitor with an IC₅₀ of 320 pM. Tofersen mediates RNase H-dependent degradation of SOD1 mRNA to reduce SOD1 protein levels in cerebrospinal fluid and serum. Tofersen downregulates cerebrospinal fluid neurofilament light chain, neurofilament heavy chain, amyloid-beta 1-40, amyloid-beta 1-42, neuropeptide Y, ubiquitin C-terminal hydrolase L1, neuropentraxins 1, 2, R, corticotropin-releasing hormone, IL-15, and serum neurofilament light chain, neurofilament heavy chain. Tofersen can be used for the research of superoxide dismutase 1-associated amyotrophic lateral sclerosis.

HY-W707693

Scyllo-Inositol-d6

Scyllo-Inositol-d₆ is the deuterium labeled Scyllo-Inositol (HY-W010041). Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks